title: Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.
abstract: OBJECTIVE
  To compare autologous bone marrow (BM) with peripheral-blood progenitor cells (PBPC) as hematopoietic rescue after high-dose chemotherapy (HDCT).
  
  
  METHODS
  From January 1991 until April 1993, 47 consecutive patients with relapsed or refractory germ cell tumors were randomized to either BM harvest or collection of PBPC mobilized by chemotherapy plus granulocyte colony-stimulating factor (G-CSF). After additional conventional-dose salvage treatment, all patients received HDCT with carboplatin 1,500 mg/m2, etoposide 2,400 mg/m2, and ifosfamide 10 g/m2 with either BM or PBPC rescue.
  
  
  RESULTS
  Forty-six patients were assessable for hematologic reconstitution, and one patient died on day +4 before engraftment. Rescue using PBPC resulted in a significantly shorter recovery time to neutrophil counts more than 500/microL (10.0 v 11.0 days, P < .01), neutrophil counts more than 1,000/microL (10.0 v 12.0 days, P = .001), and platelet counts more than 20,000/microL (10.0 v 17.0 days, P < .01), as well as in fewer days to transfusion independence from RBCs (8.0 v 12.0, P < .05) and platelets (9.0 v 12.0, P < .01) and fewer days of intravenous (IV) antibiotics (9.0 v 11.0, P < .05). However, no statistical differences in transfusion requirements or in other clinical outcome variables were observed. Overall survival and event-free survival also were not different in the two study arms.
  
  
  CONCLUSIONS
  We conclude that the use of PBPC mobilized by chemotherapy plus G-CSF results in sustained trilineage reconstitution after HDCT, which occurs more rapidly as compared with BM. The earlier hematologic reconstitution in patients with PBPC rescue significantly reduces the time to transfusion independence.
authors.affiliation: Abteilung für Innere Medizin mit Schwerpunkt Hämatologie und Onkologie, Universitätsklinikum Rudolf Virchow, Freie Universität Berlin, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Beyer
authors.forename: N
authors.initials: N
authors.lastname: Schwella
authors.forename: J
authors.initials: J
authors.lastname: Zingsem
authors.forename: I
authors.initials: I
authors.lastname: Strohscheer
authors.forename: I
authors.initials: I
authors.lastname: Schwaner
authors.forename: H
authors.initials: H
authors.lastname: Oettle
authors.forename: S
authors.initials: S
authors.lastname: Serke
authors.forename: D
authors.initials: D
authors.lastname: Huhn
authors.forename: W
authors.initials: W
authors.lastname: Stieger
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D018237:Germinoma / Q000628:therapy*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000628:therapy*; D011446:Prospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced / Q000628:therapy*
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D016190:Carboplatin; D002945:Cisplatin; D007069:Ifosfamide